Nature Immunology: doi: /ni Supplementary Figure 1. Infection strategy.
|
|
- Daniela Gardner
- 5 years ago
- Views:
Transcription
1 Supplementary Figure 1 Infection strategy. To test the antibody responses against influenza viruses, animals were sequentially infected with two divergent strains of the same subtype. For H1N1 infections, animals were primed with a human seasonal strain from 1999 (NC99, A/New Caledonia/20/1999), followed by the 2009 human pandemic H1N1 strain (NL09, A/Netherlands/602/2009) six weeks later. These viruses express divergent HA head domains, but similar HA stalk domains. For H3N2 infection animals were primed with a human seasonal strain from 1982 (Phil82, A/Philippines/2/1982), followed by a 2011 human seasonal strain (Vic11, A/Victoria/361/2011). These viruses are separated by almost 30 years of antigenic drift.
2 Supplementary Figure 2 Viral titers on day 2 after infection in animal models. Mice (A, n=5/virus), Guinea pigs (B, n=2/virus) and ferrets (C, n=2/virus) were infected with NC99, NL09, Phil82 and Cal09 and viral titers were measured on day 2 post infection from nasal wash (guinea pigs and ferrets) or nasal turbinates (mice).
3 Supplementary Figure 3 Heat-map presentation of guinea pig antibody titers after infection. A) Anti-HA titers of guinea pigs (n=3) after one H1N1 (NC99) infection. B) Anti-HA titers of guinea pigs (n=3) after sequential infection with two divergent H1N1 (NC99, NL09) strains. C) Anti-HA titers of guinea pigs (n=3) after one H3N2 (Phil82) infection. D) Anti-HA titers of guinea pigs (n=2) after sequential infection with two divergent H3N2 (Phil82, Vic11) strains. E-H) Anti-NA titers of the corresponding sera to panels A-D.
4 Supplementary Figure 4 Heat-map presentation of ferret antibody titers after infection. A) Anti-HA titers of ferrets (n=2) after one H1N1 (NC99) infection. B) Anti-HA titers of ferrets (n=2) after sequential infection with two divergent H1N1 (NC99, NL09) strains. C) Anti-HA titers of ferrets (n=2) after one H3N2 (Phil82) infection. D) Anti-HA titers of ferrets (n=2) after sequential infection with two divergent H3N2 (Phil82, Vic11) strains. E-H) Anti-NA titers of the corresponding sera to panels A-D.
5 Supplementary Figure 5 Profiles of the titers of cross-reactive antibodies after a single infection in animal models. Antibody titers measured by ELISA after single influenza virus infection were plotted on the y-axis and the percent amino acid difference to the HA of the strain used for the (later) second infection was plotted on the x-axis. Each point represents the geometric mean titer measured against a single HA (dark blue dot for H1 HAs, light blue dot for other group 1 HAs, dark red triangle for H3 HAs, light red triangle for other group 2 HAs). A non-linear fit (plateau followed by one phase decay) was performed to illustrate the differences in the breadth of the antibody response in all animals. Points for HAs with titers lower than 10 3 are plotted at A) Mouse group 1 HA titers after H1N1 (NC99) infection. ELISAs were performed on pooled sera of 10 mice and geometric mean titers of technical duplicates are shown. B) Guinea pig group 1 HA titers after H1N1 (NC99) infection. ELISAs were performed on individual sera of 3 guinea pigs and geometric mean titers are shown. C) Ferret group 1 HA titers after H1N1 (NC99) infection. ELISAs were performed on individual sera of 2 ferrets and geometric mean titers are shown. D) Mouse group 2 HA titers after H3N2 (Phil82) infection. ELISAs were performed on pooled sera of 10 mice and geometric mean titers of technical duplicates are shown. E) Guinea pig group 2 HA titers after H3N2 (Phil82) infection. ELISAs were performed on individual sera of 3 guinea pigs and geometric mean titers are shown. F Ferret group 2 HA titers after H3N2 (Phil82) infection. ELISAs were performed on individual sera of 2 ferrets and geometric mean titers are shown.
6 Supplementary Figure 6 Glycosylation versus antibody titers after infection. A-C) Antibody titers post 2x infection with either H1N1 (circles) or H3N2 (triangles) against H1 (blue) or H3 (red) HAs were plotted against the number of corresponding glycosylation sites of each HA for all animal models. Mouse samples show the geometric mean of technical duplicates of pooled sera from 10 mice per virus. Guinea pigs show the geometric mean titers of individual animals (H1N1: n=3, H3N2: n=2). For ferrets, the geometric mean titers of individual animals (n=2/virus) is shown. D) Human antibody titers (geometric mean) post ph1n1 (Cal09, n=9) or H3N2 (Vic11, n=10) infection were plotted against the number of glycosylation sites of the corresponding HAs. Circles indicate titers for individuals infected with ph1n1 and triangles indicate titers for individuals infected with H3N2. Symbols for titers measured against H1 HAs are colored red and symbols for titers measured against H3 HAs are colored blue.
7 Supplementary Figure 7 Profiles of the titers of cross-reactive antibodies after infection of humans with influenza virus. A) Geometric mean antibody titers of human individuals post ph1n1 infection (n=9) were plotted on the y-axis and the percent amino acid difference to the HA of the infection strain was plotted on the x-axis. Each point represents the geometric mean titer of all individuals measured against a single HA. Dots illustrate group 1 HAs, triangles group 2 HAs and squares influenza B HA. The postinfection titers are shown in color (blue for group 1, red for group 2 and green for influenza B) and the corresponding pre-infection titers are plotted in gray. A non-linear fit (plateau followed by one phase decay) was performed to illustrate the breadth of the antibody response. B) Geometric mean antibody titers of human individuals post H3N2 infection (n=10) were plotted in the same manner as panel A.
8 Supplementary Figure 8 ELISA of the titers of antibody to HA in humans before and after infection. A) Heat map representation of pre-ph1n1 infection ELISA antibody titers against HA (geometric mean of 9 individuals). B) Heat map representation of post-ph1n1 infection ELISA antibody titers against HA (geometric mean of 9 individuals). C) Heat map representation of pre-h3n2 infection ELISA antibody titers against HA (geometric mean of 10 individuals). B) Heat map representation of post-h3n2 infection ELISA antibody titers against HA (geometric mean of 10 individuals).
9 Supplementary Figure 9 Human reactivity to NA before and after infection. Heat map representations of human geometric mean ELISA antibody titers against NA pre- and post-ph1n1 (A, B, n=9) or H3N2 (C, D, n=10) infections. E-F) Heat map representations of geometric mean fold-induction of antibody titers against NA post H1N1 (E, n=9) or H3N2 (F, n=10) infection in humans. G-H) Geometric mean fold-induction of antibody titers against NA post-ph1n1 (n=9) or post-h3n2 (n=10) infection in humans were sorted by highest induction in a bar graph. Blue bars represent group 1 NAs, red bars group 2 NAs, green influenza B NA and grey the N10 bat isolate. Error bars indicate the 95% confidence intervals.
10 Supplementary Figure 10 Heat-map presentation of ELISA of titers of human antibodies to HA and NA (geometric mean values), separated by age group. A) Geometric mean anti-ha titers of year olds (n=30). B) Geometric mean anti-na titers of year olds (n=30). C) Geometric mean anti-ha titers of year olds (n=30). D) Geometric mean anti-na titers of year olds (n=30). E) Geometric mean anti-ha titers of year olds (n=30). F) Geometric mean anti-na titers of year olds (n=30).
11 Supplementary Figure 11 Serum-transfer experiment. For each virus challenge, serum samples of 30 individuals per age group were pooled, sterile filtrated and 250 l of serum intraperitoneally injected into 10 mice for each group. An equal number of mice received immunoglobulin depleted serum as a negative control group. Two hours after the serum transfer, mice were anesthetized and infected with PFU of virus diluted in PBS (50 l total volume) intranasally. Five mice each were euthanized on days 3 and 6, their lungs extracted and viral titers measured by plaque assay.
12 Supplementary Tables Suppl. Table 1: Characteristics of the naturally infected individuals Patient Age Gender Subtype* Diagnostic Sera Technique (d.p.i.) P Y M H1N1pdm09 HI/qRT-PCR 1/21 P Y M H1N1pdm09 HI/qRT-PCR 1/21 P Y M H1N1pdm09 qrt-pcr 1/21 P Y F H1N1pdm09 HI 1/21 P Y F H1N1pdm09 HI/qRT-PCR 1/21 P Y F H1N1pdm09 qrt-pcr 1/21 P Y M H1N1pdm09 qrt-pcr 1/21 P Y F H3N2 HI/qRT-PCR 1/21 P Y M H3N2 HI 1/21 P Y F H3N2 RT-PCR 1/21 P Y M H3N2 HI/RT-PCR 1/21 P Y M H3N2 HI 1/28 P Y F H3N2 HI/RT-PCR 1/28 P M M H3N2 Seq 1/28 P Y F H3N2 HI 1/28 P Y M H1N1pdm09 HI/qRT-PCR 1/28 P Y M H1N1pdm09 qrt-pcr 1/28 P Y M H3N2 HI/RT-PCR 1/28 P Y F H3N2 HI 1/28 *Strains were subtyped by RT-PCR and/or HI, Y =Years; M = Months; F =Female; M = Male; d.p.i.: day post infection.
13 Suppl. Table 2: Virus strains used in this study Abbreviation Subtype HA NA Backbone NL09 H1N1 A/Netherlands/602/09 A/Netherlands/602/09 A/Netherlands/602/09 NC99 H1N1 A/New Caledonia/20/99 A/New Caledonia/20/99 A/New Caledonia/20/99 H1N8 H1N8 A/New A/mallard/Sweden/50/02 A/PR/8/34 Caledonia/20/99 Phil82 H3N2 A/Philippines/2/82 A/Philippines/2/82 A/PR/8/34 Vic11 H3N2 A/Victoria/361/11 A/Victoria/361/11 A/Victoria/361/11 H3N8 H3N8 A/Philippines/2/82 A/mallard/Sweden/50/02 A/PR/8/34 H4N8 H4N8 A/duck/Czech/56 A/mallard/Sweden/50/02 A/PR/8/34 H5N8 H5N8 A/Vietnam/1203/04* A/mallard/Sweden/50/02 A/PR/8/34 H7N8 H7N8 A/Shanghai/1/13 A/mallard/Sweden/50/02 A/PR/8/34 H9N4 H9N4 A/guinea fowl/hk/wf10/99 A/mallard/Sweden/24/02 A/PR/8/34 * multibasic cleavage site was removed, low pathogenicity virus
14 Suppl. Table 3: Recombinant HA and NA proteins used in this study Subtype Abbreviation Strain Name From subtype N-linked glycosylation sites* H1 PR8 A/PR/8/34 H1N1 6 H A/South Carolina/1/18 H1N1 6 H1 NC99 A/New Caledonia/20/99 H1N1 9 H1 Cal09 A/California/04/09 H1N1 7 H1 FM47 A/Fort Monmouth/1/47 H1N1 7 H1 swjian11 A/swine/Jiangsu/40/11 H1N1 6 H2 Jap57 A/Japan/305/57 H2N2 6 H2 maneth99 A/mallard/Netherlands/5/99 H2N9 7 H3 HK68 A/Hong Kong/1/68 H3N2 7 H3 Phil82 A/Philippines/2/82 H3N2 9 H3 Vic11 A/Victoria/361/11 H3N2 13 H3 Indi11 A/Indiana/10/11 H3N2 8 H3 semass11 A/harbor seal/massachusetts/1/11 H3N8 7 H3 cntexa04 A/canine/Texas/1/04 H3N8 7 H4 duczec56 A/duck/Czech/68 H4N6 5 H5 VN04 A/Vietnam/1203/04 H5N1 8 H5 Indo05 A/Indonesia/5/05 H5N1 9 H6 maswed02 A/mallard/Sweden/81/02 H6N1 7 H7 SH13 A/Shanghai/1/13 H7N9 5 H7 ckjali12 A/chicken/Jalisco/12283/12 H7N3 5 H8 maswed02 A/mallard/Sweden/24/02 H8N4 7 H9 gfhoko99 A/guinea fowl/hk/wf10/99 H9N2 9 H10 malnal10 A/mallard/Interior H10N7 6 Alaska/10BM01929/10 H11 shneth99 A/shoveler/Netherlands/18/99 H11N9 7 H12 malnal07 A/mallard/Interior H12N5 9 Alaska/7MP0167/07 H13 guswed99 A/black headed gull/sweden/1/99 H13N6 7 H14 maastr82 A/mallard/Gurjev/263/82 H14N5 7 H15 swweau79 A/shearwater/West Australia/2576/79 H15N9 7 H16 guswed99 A/black headed gull/sweden/5/99 H16N3 7 H17 btguat10 A/yellow shouldered H17N10 6 bat/guatemala/060/10 H18 btperu10 A/bat/Peru/33/10 H18N11 7 N1 Cal09 A/California/04/09 H1N1 N1 VN04 A/Vietnam/1203/04 H5N1 N1 Texa91 A/Texas/36/91 H1N1 N2 Sing57 A/Singapore/1/57 H2N2 N2 HK68 A/Hong Kong/1/68 H3N2 N2 Vic11 A/Texas/50/12 H3N2 N3 swmiss06 A/swine/Missouri/ /06 H2N3 N4 maswed02 A/mallard/Sweden/24/02 H8N4 N5 maswed03 A/mallard/Sweden/86/03 H12N5 N6 maneth99 A/mallard/Netherlands/1/99 H4N6 N7 macali10 A/mallard/Interior Alaska/10BM01929/10 H10N7
15 N8 maswed02 A/mallard/Sweden/50/02 H3N8 N9 Anhu13 A/mallard/Sweden/36/03 H11N9 N10 N10 A/yellow shouldered H17N10 bat/guatemala/060/10 B HA Yam88 B/Yamagata/16/88 B 8 B NA Yam88 B/Yamagata/16/88 B *Predicted for the HA ectodomain using NetNGlyc 1.0 server
16 Suppl. Table 4: Characteristics of the three age cohorts Age group Sex Race M 16 (53.3%) Black 9 (30%) F 14 (46.7%) Caucasian 17 (56.7%) Hispanic 4 (13.3%) M 15 (50%) Black 7 (23.3%) F 15 (50%) Caucasian 18 (60%) Hispanic 5 (16.7%) M 15 (50%) Black 6 (20%) F 15 (50%) Caucasian 24 (80%) Hispanic 0 (0%)
r e s o u r c e 2017 Nature America, Inc., part of Springer Nature. All rights reserved. advance ONLINE PUBLICATION nature immunology
Defining the antibody cross-reactome directed against the influenza virus surface glycoproteins Raffael Nachbagauer 1, Angela Choi 1,2, Ariana Hirsh 1, Irina Margine 1, Sayaka Iida 3, Aldo Barrera 4, Marcela
More informationH3N2 Mismatch of Northern Hemisphere Influenza Vaccines and Head-to- head Comparison between Human and Ferret Antisera derived Antigenic Maps
1 2 H3N2 Mismatch of 2014 15 Northern Hemisphere Influenza Vaccines and Head-to- head Comparison between Human and Ferret Antisera derived Antigenic Maps 3 4 5 6 7 Hang Xie 1*, Xiu-Feng Wan 2*, Zhiping
More informationStudying Repeated Immunization in an Animal Model. Kanta Subbarao Laboratory of Infectious Diseases, NIAID
Studying Repeated Immunization in an Animal Model Kanta Subbarao Laboratory of Infectious Diseases, NIAID Animal models in Influenza Research Commonly used Mice Ferrets Guinea pigs Non human primates Less
More informationInfluenza A Virus Transmission Bottlenecks Are Defined by Infection Route and Recipient Host
Cell Host & Microbe, Volume 16 Supplemental Information Influenza A Virus Transmission Bottlenecks Are Defined by Infection Route and Recipient Host Andrew Varble, Randy A. Albrecht, Simone Backes, Marshall
More informationRe-engineering HA as a strategy to develop universal influenza vaccines
WHO Integrated Meeting on Development & Clinical Trials of Influenza Vaccines Re-engineering HA as a strategy to develop universal influenza vaccines Harry Kleanthous, Ph.D. Discovery Research January
More informationNASDAQ:NVAX Novavax, Inc. All rights reserved.
Novavax vaccine induced improved immune responses against homologous and drifted A(H3N2) viruses in older adults compared to egg-based, high-dose, influenza vaccine World Vaccine Congress April 4, 2018
More informationWHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines: Update
WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines: Update 23 July 2009 Introduction This document updates guidance 1 from the World
More informationRussian-backbone LAIV history and clinical development. L.Rudenko Institute of Experimental Medicine, St. Petersburg, Russia
Russian-backbone LAIV history and clinical development L.Rudenko Institute of Experimental Medicine, St. Petersburg, Russia EFFECTIVENESS OF LIVE COLD-ADAPTED INFLUENZA VACCINE FOR ADULTS. SUMMARY FROM
More informationHemagglutinin-stalk specific antibodies: How to induce them and how to measure them
Immunodominant head domain Stalk domain Hemagglutinin-stalk specific antibodies: How to induce them and how to measure them Florian Krammer Icahn School of Medicine at Mount Sinai May 5 th 2014 2 nd WHO
More informationWhat are ADCC antibodies? Work on influenza ADCC antibodies Greenberg et al, Hashimoto et al. First describes Fluspecific
14/7/214 Acknowledgement antibodies against diverse influenza strains: Implications for universal vaccination Sinth Jegaskanda PhD Prof Stephen Kent University of Melbourne What are antibodies? Work on
More informationUNIVERSAL INFLUENZA VIRUS VACCINES Adolfo García Sastre. Icahn School of Medicine at Mount Sinai, New York
UNIVERSAL INFLUENZA VIRUS VACCINES Adolfo García Sastre Icahn School of Medicine at Mount Sinai, New York INFLUENZA VIRUSES PAx B EPIDEMIOLOGY OF HUMAN INFLUENZA VIRUSES A H1N1 H3N2 1968 H2N2 1957 H1N1
More informationTOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE
TOWARDS A UNIVERSAL INFLUENZA VIRUS VACCINE Peter Palese Icahn School of Medicine at Mount Sinai New York OPTIONS IX 8-26-16 ISIRV - Options IX for the Control of Influenza Peter Palese, PhD Professor
More informationSex, viruses, and the statistical physics of evolution
Sex, viruses, and the statistical physics of evolution Cartoon of Evolution A TC G Selection Genotypes Mutation & Recombination Mutation...ATACG... Sex & Recombination Selection...ATGCG... Richard Neher
More informationPredicting the future
Swine influenza A viruses: a more global picture Predicting the future Dr Nicola S. Lewis BSc BVetMed PhD MRCVS Dr Nicola S. Lewis BSc BVetMed PhD MRCVS Centre for for Pathogen Evolution and WHO Collaborating
More informationThe DBA.2 Mouse Is Susceptible to Disease following Infection with a Broad, but Limited, Range of Influenza A and B Viruses
JOURNAL OF VIROLOGY, Dec. 2011, p. 12825 12829 Vol. 85, No. 23 0022-538X/11/$12.00 doi:10.1128/jvi.05930-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. The DBA.2 Mouse Is Susceptible
More informationIncorporating virologic data into seasonal and pandemic influenza vaccines
Incorporating virologic data into seasonal and pandemic influenza vaccines Kanta Subbarao WHO Collaborating Centre for Reference and Research on Influenza & Department of Microbiology and Immunology, University
More informationPRODUCTS CATALOG OUR MISSION:
PRODUCTS CATALOG OUR MISSION: TO SAVE LIVES AND IMPROVE HEALTH BY EFFECTIVELY RESPONDING TO OUR CHANGING WORLD WITH INNOVATIVE VACCINES AND BIOPHARMACEUTICALS TABLE OF CONTENTS 3 Influenza Research Antigens
More informationMin Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention. June 18, 2015 NIBSC
Workshop on Immunoassay Standardization for Universal Flu Vaccines Min Levine, Ph. D. Influenza Division US Centers for Disease Control and Prevention June 18, 2015 NIBSC 1 Multiple Immune Mechanisms Contribute
More informationClinical Trials of Pandemic Vaccines: Key Issues. John Treanor University of Rochester Rochester, NY
Clinical Trials of Pandemic Vaccines: Key Issues John Treanor University of Rochester Rochester, NY Inactivated vaccine approach Proven technology Used successfully in 1957 and 1968 Abundant efficacy data
More informationIdentification of novel influenza A viruses in Australian swine
Identification of novel influenza A viruses in Australian swine OFFLU SIV Group Annual Meeting, Rome, 16-17 April 2013 Frank Wong 1, Ian Barr 2, David Smith 3, David Williams 1, Kelly Davies 1, Vicky Stevens
More informationApplication of Reverse Genetics to Influenza Vaccine Development
NIAID Application of Reverse Genetics to Influenza Vaccine Development Kanta Subbarao Laboratory of Infectious Diseases NIAID, NIH Licensed Vaccines for Influenza Principle: Induction of a protective
More informationActive and Passive Immunization for Avian Influenza Virus Infections
NIAID Active and Passive Immunization for Avian Influenza Virus Infections Kanta Subbarao, MD, MPH Laboratory of Infectious Diseases NIAID, NIH Immortalizing H5 HA-Specific Memory B Cells Collection of
More informationInfluenza or flu is a
Clinical and Research Area Infectious Diseases Influenza Virus Types A and B Influenza or flu is a respiratory illness that is caused by influenza viruses. Influenza viruses type A and type B cause seasonal
More information2009 H1N1 Influenza ( Swine Flu ) Hemagglutinin ELISA kit
2009 H1N1 Influenza ( Swine Flu ) Hemagglutinin ELISA kit Catalog Number : SEK001 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as
More informationSupporting Information
Supporting Information Valkenburg et al. 10.1073/pnas.1403684111 SI Materials and Methods ELISA and Microneutralization. Sera were treated with Receptor Destroying Enzyme II (RDE II, Accurate) before ELISA
More informationSupplementary Figure 1.
Supplementary Figure 1. Female Pro-ins2 -/- mice at 5-6 weeks of age were either inoculated i.p. with a single dose of CVB4 (1x10 5 PFU/mouse) or PBS and treated with αgalcer or control vehicle. On day
More informationThe Influenza A (H1N1
The Influenza A (H1N1 Human Swine) Pandemic North America (A/Mexico/ /2009 [H1N1]), Influenza A virus, April 2009: - H1N1 & H3N2 viruses are endemic among pig populations in many countries - Reassortment
More informationH5N1 and H7 LAIV-IAV Prime-Boost Studies
NIAID H5N1 and H7 LAIV-IAV Prime-Boost Studies Kanta Subbarao, MD, MPH NIAID, NIH The LID Pandemic Influenza Vaccine Program Program: CRADA with MedImmune Clinical Trials: Center for Immunization Research,
More informationUpdate on influenza monitoring and vaccine development
Update on influenza monitoring and vaccine development Annette Fox WHO Collaborating Centre for Reference and Research on Influenza at The Peter Doherty Institute for Infection and Immunity 1 Outline Why
More informationGlobal Influenza Virus Surveillance and WHO Influenza Vaccine Virus Recommendations for the Northern Hemisphere Influenza Season
Global Influenza Virus Surveillance and WHO Influenza Vaccine Virus Recommendations for the Northern Hemisphere 2015-16 Influenza Season Jacqueline Katz, Ph. D. Deputy Director (acting), Influenza Division
More informationTable S1. X-ray data collection and refinement statistics
Table S1. X-ray data collection and refinement statistics Data collection H7.167 Fab-Sh2/H7 complex Beamline SSRL 12-2 Wavelength (Å) 0.97950 Space group I2 1 3 Unit cell parameters (Å, º) a = b = c=207.3,
More informationRecommended composition of influenza virus vaccines for use in the influenza season
Recommended composition of influenza virus vaccines for use in the 2006 2007 influenza season This recommendation relates to the composition of vaccines for the forthcoming influenza season in the northern
More informationE.J. Remarque & G. Koopman. Confiden'al 2
EDUcate influenza VACcine A Combinatorial immunization strategy to educate the immune system towards cross recognition and coverage against antigenic drift in seasonal influenza virus exposure Confiden'al
More informationSynthetic Genomics and Its Application to Viral Infectious Diseases. Timothy Stockwell (JCVI) David Wentworth (JCVI)
Synthetic Genomics and Its Application to Viral Infectious Diseases Timothy Stockwell (JCVI) David Wentworth (JCVI) Outline Using informatics to predict drift (strain selection) Synthetic Genomics: Preparedness
More informationTECHNICAL DOCUMENT. Influenza virus characterisation. Influenza A(H3N2) virus analysis. Summary Europe, December Summary
Community Network of Reference Laboratories (CNRL) for Human Influenza in Europe Influenza virus characterisation Summary Europe, December 2011 Summary Since week 40/2011, influenza A(H1N1)pdm09, influenza
More informationInfluenza A H1N1 (Swine Flu 2009) Hemagglutinin / HA ELISA Pair Set
Influenza A H1N1 (Swine Flu 2009) Hemagglutinin / HA ELISA Pair Set Catalog Number : SEK001 To achieve the best assay results, this manual must be read carefully before using this product and the assay
More informationSUPPLEMENTARY INFORMATION
doi:10.1038/nature12391 Table 1. Binding of A(H7N9) viruses to individual glycan structures. # Structure a Anhui1 Shanghai1 1 Neu5Acα nb nb 2 Neu5Acα ++ nb 3 Neu5Acβ nb nb 4 Neu5Acα2-3(6-O-Su)Galβ1-4GlcNAcβ
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY INFORMATION doi:10.1038/nature10831 1. Pathological analyses of H5 avian-human reassortant viruses. The rgca04 infection in the lungs of ferrets mainly caused severe bronchopneumonia with
More informationHeat-killed Lactobacillus casei
Heat-killed Lactobacillus casei confers broad protection against influenza A virus primary infection and develops heterosubtypic immunity against future secondary infection Yu-Jin Jung, Young-Tae Lee,
More informationRESPIRATORY VIRUS SURVEILLANCE REPORT
RESPIRATORY VIRUS SURVEILLANCE REPORT Week Ending January 20, 2018 Wisconsin Department of Health Services Division of Public Health Bureau of Communicable Diseases Communicable Diseases Epidemiology Section
More informationEvaluation of Anigen H5 Avian Influenza Virus Antigen Rapid Test Kit
Evaluation of Anigen H5 Avian Influenza Virus Antigen Rapid Test Kit Evaluation period: Mar. 2004 ~Dec. 2004 Sung Hwan Woo, Y. J. Lee, J. G. Choi, E.K. Lee, Y.K. Kwon, J. H. Kim, Avian Disease Division,
More informationTargeted disruption of influenza A virus hemagglutinin in genetically modified. mice reduces viral replication and improves disease outcome
Supplementary Information Targeted disruption of influenza A virus hemagglutinin in genetically modified mice reduces viral replication and improves disease outcome Song Wang 1#, Chao Chen 1#, Zhou Yang
More informationBlocking Interhost Transmission of Influenza Virus by Vaccination in the Guinea Pig Model
JOURNAL OF VIROLOGY, Apr. 2009, p. 2803 2818 Vol. 83, No. 7 0022-538X/09/$08.00 0 doi:10.1128/jvi.02424-08 Copyright 2009, American Society for Microbiology. All Rights Reserved. Blocking Interhost Transmission
More informationRelative activity (%) SC35M
a 125 Bat (H17N) b 125 A/WSN (H1N1) Relative activity (%) 0 75 50 25 Relative activity (%) 0 75 50 25 0 Pos. Neg. PA PB1 Pos. Neg. NP PA PB1 PB2 0 Pos. Neg. NP PA PB1 PB2 SC35M Bat Supplementary Figure
More informationCross-Reactivity to Field Isolates of Canine Influenza Virus by a Killed Canine Influenza Virus (H3N8, Iowa05) Vaccine
Cross-Reactivity to Field Isolates of Canine Influenza Virus by a Killed Canine Influenza Virus (H3N8, Iowa05) Vaccine Nancee Oien, B.S., M.S. a Sally Mattern, B.S a Jaime Brozowski, B.S., M.S. b Janet
More informationSupplemental Information Dose Response Parameters for Gain of Function Pathogens
Supplemental Information Dose Response Parameters for Gain of Function Pathogens Infection Dose-Response To quantify the likelihood of an individual or animal becoming infected from exposure to virus,
More informationTECHNICAL DOCUMENT Community Network of Reference Laboratories (CNRL) for Human Influenza in Europe. Influenza virus characterisation
Community Network of Reference Laboratories (CNRL) for Human Influenza in Europe Influenza virus characterisation Summary Europe, January 2010 A(H1N1pdm) viruses have continued to predominate. Surveillance
More informationThe influenza A viruses of swine in Japan, Thailand, and Vietnam
The influenza A viruses of swine in Japan, Thailand, and Vietnam Takehiko Saito Division of Transboundary Animal Disease, National Institute of Animal Health, National Agriculture and Food Research Organization,
More informationPreferential induction of cross-group influenza A hemagglutinin stem specific memory B cells after H7N9 immunization in humans
INFECTIOUS DISEASE Preferential induction of cross-group influenza A hemagglutinin stem specific memory B cells after immunization in humans Sarah F. Andrews, 1 * M. Gordon Joyce, 1 Michael J. Chambers,
More informationSurveillance Overview
Number of Positive Specimens Percent Positive Number of Positive Specimens National Center for Immunization & Respiratory Diseases 2016-17 Surveillance Overview Lynnette Brammer, MPH Epidemiologist, Influenza
More informationvirus characterisation
SURVEILLANCE REPORT Influenza Influenza virus virus characterisation Summary Summary Europe, Europe, February July 2012 2013 Summary During the 2012/2013 season A(H1N1)pdm09, A(H3N2) and B/Victoria- and
More informationChinese Influenza Weekly Report
Chinese Influenza Weekly Report (All data are preliminary and may change as more reports are received) Summary During week 5, influenza activity is at intra-seasonal levels both in southern and northern
More informationChinese Influenza Weekly Report
Chinese Influenza Weekly Report (All data are preliminary and may change as more reports are received) Summary During week 13, influenza activity was still a little high in mainland China, and it was increasing
More informationph1n1 H3N2: A Novel Influenza Virus Reassortment
ph1n1 H3N2: A Novel Influenza Virus Reassortment Jonathan Gubbay Medical Microbiologist Public Health Laboratory Public Health Ontario June 16, 2011 ph1n1 H3N2 Reassortment: Talk Overview Explain strain
More information7/14/2014 VACCINE-INDUCED ANTI-HA2 ANTIBODIES PROMOTE VIRUS FUSION AND ENHANCE INFLUENZA VIRUS RESPIRATORY DISEASE (VAERD)
7/14/214 VACCINATION & ENHANCED DISEASE VACCINE-INDUCED ANTI-HA2 ANTIBODIES PROMOTE VIRUS FUSION AND ENHANCE INFLUENZA VIRUS RESPIRATORY DISEASE (VAERD) HANA GOLDING & SURENDER KHURANA DIVISION OF VIRAL
More information1918 Influenza; Influenza A, H1N1. Basic agent information. Section I- Infectious Agent. Section II- Dissemination
1918 Influenza; Influenza A, H1N1 Basic agent information Section I- Infectious Agent Risk Group: - RG3 Synonym or Cross reference: - Spanish Flu - 1918 Flu - El Grippe Characteristics: - SELECT AGENT
More informationREAGENTS FOR THE TYPING OF HUMAN INFLUENZA ISOLATES 2017
REAGENTS FOR THE TYPING OF HUMAN INFLUENZA ISOLATES 2017 This product was developed by the Victorian Infectious Diseases Reference Laboratory (VIDRL) in its capacity as a WHO Collaborating Centre for Reference
More informationMASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH WEEKLY INFLUENZA UPDATE January 26, 2018
MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH WEEKLY INFLUENZA UPDATE January 26, 2018 All data in this report are preliminary and subject to change as more information is received. Sentinel Provider Surveillance:
More informationvirus characterisation
SURVEILLANCE REPORT Influenza Influenza virus virus characterisation Summary Europe, July 2012 Summary Since 1 January 2012, influenza A(H1N1)pdm09, influenza A(H3N2) and influenza B/Victoria and B/Yamagata
More informationLars R. Haaheim ( ) PhD, Professor Emeritus, University of Bergen, Norway
Lars R. Haaheim (1945-2011) PhD, Professor Emeritus, University of Bergen, Norway Licensing requirements a personal perspective John M Wood Summer School on Influenza, Siena August 1-5 2011 National Institute
More informationAntigenic drift caused by periodic amino acid changes on the
A Pan-H1 Anti-Hemagglutinin Monoclonal Antibody with Potent Broad-Spectrum Efficacy In Vivo Gene S. Tan, Florian Krammer, Dirk Eggink, Alita Kongchanagul, Thomas M. Moran, and Peter Palese Department of
More informationChallenges and Solutions for the Next Generation of Vaccines: Jonathan Liu Luis Maranga Sachin Mani Richard Schwartz
Challenges and Solutions for the Next Generation of Vaccines: Development of fcell llculture-based dlive Attenuated t Influenza Vaccine VACCINE TECHNOLOGY II June 1, 2008 Albufeira (near Faro), Algarve,
More informationChinese Influenza Weekly Report
National Institute for Viral Disease Control and Prevention, China CDC Chinese Weekly Report (All data are preliminary and may change as more reports are received) Summary During week 17, influenza activity
More informationPATH Influenza Vaccine Projects
PATH Influenza Vaccine Projects Overview John W. Boslego, MD John Boslego Director, Vaccine Development Global Program March 25 th, 2014 Influenza Vaccine Project (IVP) at PATH IVP Goal: Advance the development
More informationSupplementary Figure 1 Schematic overview of the mutant virus libraries and their
Supplementary Figure 1 Schematic overview of the mutant virus libraries and their consecutive passages in MDCK cells. All nine virus libraries were passaged twice in MDCK cells. Then, aliquots of all nine
More informationNanoparticulate Vaccine Design: The VesiVax System
Nanoparticulate Vaccine Design: The VesiVax System Gary Fujii, Ph.D. President and CEO Molecular Express, Inc. May 16, 2006 Orlando, Florida Influenza Each year up to 20% of the world's population contracts
More informationZoonotic potential of non-avian influenza A viruses
Laboratory of Virology Faculty of Veterinary Medicine Ghent University, Belgium Zoonotic potential of non-avian influenza A viruses Prof. Kristien Van Reeth (1) Several documented cases of influenza virus
More informationQuestions and Answers
Questions and Answers Recommended composition of influenza virus vaccines for use in the southern hemisphere 2016 influenza season and development of candidate vaccine viruses for pandemic preparedness
More informationDiagnosis of H1N1 (2009) at the CSIRO Australian Animal Health Laboratory
Diagnosis of H1N1 (2009) at the CSIRO Australian Animal Health Laboratory Peter Daniels and Paul Selleck Prepared for the 2 nd OFFLU Technical Meeting OIE Paris, 15 & 16 September, 2009 AAHL holds the
More informationInfluenza: The past, the present, the (future) pandemic
Influenza: The past, the present, the (future) pandemic Kristin Butler, MLS (ASCP) cm Department of Clinical Laboratory Sciences Louisiana Health Sciences Center - Shreveport Fall 2017 Objectives 1) Detail
More informationThe "Flu" a case of low fever and sniffles that keeps you home in bed for a day a gastrointestinal upset ("stomach flu")
The "Flu" Influenza is a viral infection of the lungs characterized by fever, cough, and severe muscle aches. In the elderly and infirm, it is a major cause of disability and death (often as a result of
More informationSupporting Information Table of Contents
Supporting Information Table of Contents Supporting Information Figure 1 Page 2 Supporting Information Figure 2 Page 4 Supporting Information Figure 3 Page 5 Supporting Information Figure 4 Page 6 Supporting
More informationC E E Z A D. Rational Development of Influenza Vaccines: NDV-based influenza vaccines for poultry and livestock
C E E Z A D Center of Excellence for Emerging and Zoonotic Animal Diseases A Department of Homeland Security Center of Excellence Rational Development of Influenza Vaccines: NDV-based influenza vaccines
More informationInfluenza and other Respiratory Viruses Update
Influenza and other Respiratory Viruses Update-- 2017 Pete Shult, PhD CDD Director & Emergency Laboratory Response and Erik Reisdorf, MPH, M(ASCP) CM Surveillance and Virology Lab-Team Lead WISCONSIN STATE
More informationREPORT. Early risk assessment: What to expect of the 2017/18 influenza season in Norway
2017 REPORT Early risk assessment: What to expect of the 2017/18 influenza season in Norway Early risk assessment: What to expect of the 2017/18 influenza season in Norway Department of Influenza 2 Published
More informationTodd Davis Influenza Division Centers for Disease Control and Prevention Atlanta, GA USA
OFFLU influenza virus meeting 27 28 March 2017 FAO Headquarters, Rome, Italy Todd Davis Influenza Division Centers for Disease Control and Prevention Atlanta, GA USA Strains of concerns Influenza A(H3N2)v
More informationSupplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Supplementary Figure 1. SC35M polymerase activity in the presence of Bat or SC35M NP encoded from the phw2000 rescue plasmid. HEK293T
More information(the change introduced is to add a risk assessment, missing from the previous version, for small-scale laboratory work with characterized CVV)
Update of WHO biosafety risk assessment and guidelines for the production and quality control of human influenza vaccines against avian influenza A(H7N9) virus As of 23 May 2013 (replaces version of 10
More informationThis product was developed by the Victorian Infectious Diseases Reference Laboratory (VIDRL) in its capacity as a WHO Collaborating Centre for
This product was developed by the Victorian Infectious Diseases Reference Laboratory (VIDRL) in its capacity as a WHO Collaborating Centre for Reference and Research on Influenza, with material provided
More informationvirus characterisation
SURVEILLANCE REPORT Influenza Influenza virus virus characterisation Summary Europe, March July 2012 2013 Summary During the 2012 13 season, A(H1N1)pdm09, A(H3N2) and B/Victoria- and B/Yamagata-lineage
More informationHemagglutinin (HA) and neuraminidase (NA), the major envelope
RESEARCH ARTICLE Antibody Pressure by a Human Monoclonal Antibody Targeting the 2009 Pandemic H1N1 Virus Hemagglutinin Drives the Emergence of a Virus with Increased Virulence in Mice Christopher D. O
More informationIncomplete immune response to Coxsackie B viruses. associates with early autoimmunity against insulin
Incomplete immune response to Coxsackie B viruses associates with early autoimmunity against insulin Michelle P. Ashton 1, Anne Eugster 1, Denise Walther 1, Natalie Daehling 1, Stephanie Riethausen 2,
More informationUpdate on SIV activity - Australia and Asia-Pacific
Update on SIV activity - Australia and Asia-Pacific OFFLU Swine Influenza group technical meeting 27 March 2012, OIE Paris CSIRO Australian Animal Health Laboratory CSIRO ANIMAL, FOOD AND HEALTH SCIENCE
More informationSeasonal influenza virus infections cause significant morbidity
RESEARCH ARTICLE crossmark Vaccination with Adjuvanted Recombinant Neuraminidase Induces Broad Heterologous, but Not Heterosubtypic, Cross-Protection against Influenza Virus Infection in Mice Teddy John
More informationMEETING THE STANDARDS: FDA MANDATORY RAPID INFLUENZA DETECTION TEST (RIDTs) RECLASSIFICATION
MEETING THE STANDARDS: FDA MANDATORY RAPID INFLUENZA DETECTION TEST (RIDTs) RECLASSIFICATION NOVEMBER 6, 2017 SALLY A. HOJVAT M.Sc., Ph.D. Retired as Director of FDA Division of Microbiology Devices, CDRH
More informationAn epitope of limited variability as a novel influenza vaccine target
An epitope of limited variability as a novel influenza vaccine target Craig P Thompson 1,2*, José Lourenço 1, Adam A Walters 2, Uri Obolski 1, Matthew Edmans 1,2, Duncan S Palmer 1, Kreepa Kooblall 3,
More informationHAI and NAI as Correlates of Protection After Influenza Vaccination
HAI and NAI as Correlates of Protection After Influenza Vaccination Arnold S. Monto Thomas Francis Jr. Professor University of Michigan School of Public Health Ann Arbor, Michigan Having Correlates is
More informationSUPPLEMENTAL MATERIAL: Immunity toward H1N1 influenza hemagglutinin of historical and contemporary strains suggests protection and vaccine failure
SUPPLEMENTAL MATERIAL: Immunity toward H1N1 influenza hemagglutinin of historical and contemporary strains suggests protection and vaccine failure Running Title: Immunity toward the evolving H1N1 influenza
More informationOverview of Influenza Activity and Characterizations of Viruses isolated in 2011/12 season in Northern Hemisphere
6thMeeting of NICs in the WPR and SEAR 29-31 May, 2012 Hanoi VN Overview of Influenza Activity and Characterizations of Viruses isolated in 2011/12 season in Northern Hemisphere Takato Odagiri WHO Collaborating
More informationInfluenza Genome Sequencing Project Proposal
Date of Proposal (MM/DD/YY): 06/13/12 TITLE: Role of the Untranslated Regions of the Influenza A Virus Replication and Vaccines Purpose/Objective-please provide a brief one to two paragraph description
More informationINFLUENZA IN SWINE HERDS FOLLOWING THE INTRODUCTION OF PANDEMIC 2009 H1N1
INFLUENZA IN SWINE HERDS FOLLOWING THE INTRODUCTION OF PANDEMIC 2009 H1N1 Janice Reis Ciacci Zanella PAHO Webinar December 18, 2015 INFLUENZA IN SWINE IN BRAZIL Janice Reis Ciacci Zanella Brazilian Agricultural
More informationRecommended composition of influenza virus vaccines for use in the influenza season
Recommended composition of influenza virus vaccines for use in the 2009 2010 influenza season February 2009 This recommendation relates to the composition of vaccines for the forthcoming influenza season
More informationVaccine 30 (2012) Contents lists available at SciVerse ScienceDirect. Vaccine. jou rn al h om epa ge:
Vaccine 30 (2012) 7395 7399 Contents lists available at SciVerse ScienceDirect Vaccine jou rn al h om epa ge: www.elsevier.com/locate/vaccine Possible outcomes of reassortment in vivo between wild type
More informationNature Immunology: doi: /ni Supplementary Figure 1. Gene expression profile of CD4 + T cells and CTL responses in Bcl6-deficient mice.
Supplementary Figure 1 Gene expression profile of CD4 + T cells and CTL responses in Bcl6-deficient mice. (a) Gene expression profile in the resting CD4 + T cells were analyzed by an Affymetrix microarray
More informationPreparing for the Fall Flu Season. Jonathan Gubbay Medical Microbiologist Public Health Laboratory OAHPP
Preparing for the Fall Flu Season Laboratory Perspective Jonathan Gubbay Medical Microbiologist Public Health Laboratory OAHPP September 21, 2009 Objectives 1. Review the emergence of Novel Influenza A
More informationTITLE: Influenza A (H7N9) virus evolution: Which genetic mutations are antigenically important?
TITLE: Influenza A (H7N9) virus evolution: Which genetic mutations are antigenically important? AUTHORS: Joshua G. Petrie 1, Adam S. Lauring 2,3 AFFILIATIONS: 1 Department of Epidemiology, University of
More informationChinese Influenza Weekly Report
Chinese Influenza Weekly Report (All data are preliminary and may change as more reports are received) Summary During week 10, influenza activity was still a little high in southern and northern China
More informationSupplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood
Supplementary Figure 1. ALVAC-protein vaccines and macaque immunization. (A) Maximum likelihood tree illustrating CRF01_AE gp120 protein sequence relationships between 107 Envs sampled in the RV144 trial
More informationH5N1 ( Avian Flu ) Hemagglutinin ELISA Pair Set
H5N1 ( Avian Flu ) Hemagglutinin ELISA Pair Set Catalog Number : SEK002 To achieve the best assay results, this manual must be read carefully before using this product and the assay is run as summarized
More informationIn addition to yearly epidemics, pandemic outbreaks of influenza
Antibody Breadth and Protective Efficacy Are Increased by Vaccination with Computationally Optimized Hemagglutinin but Not with Polyvalent Hemagglutinin-Based H5N1 Virus-Like Particle Vaccines Brendan
More information